1. Palmer, SC, Tendal, B, Mustafa, RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021; 372: m4573.
Google Scholar2. Zelniker, TA, Wiviott, SD, Raz, I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31–39.
Google Scholar | Crossref | Medline3. Neuen, BL, Young, T, Heerspink, H, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2019; 7: 845–854.
Google Scholar | Crossref | Medline4. Malik, AH, Yandrapalli, S, Goldberg, M, et al. Cardiovascular outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis of randomized controlled trials. Cardiol Rev 2020; 28: 116–124.
Google Scholar | Crossref | Medline5. Toyama, T, Neuen, BL, Jun, M, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab 2019; 21: 1237–1250.
Google Scholar | Crossref | Medline6. Yamada, T, Wakabayashi, M, Bhalla, A, et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol 2021; 20: 14.
Google Scholar | Crossref | Medline7. Bhatt, DL, Szarek, M, Pitt, B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 2021; 384: 129–139.
Google Scholar | Crossref | Medline8. Bhatt, DL, Szarek, M, Steg, PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021; 384: 117–128.
Google Scholar | Crossref | Medline9. Al Salah, HM, Aref, SJ, Khan, MS, et al. Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: a meta-analysis update. Am Heart J 2021; 233: 86–91.
Google Scholar | Crossref | Medline10. Moher, D, Liberati, A, Tetzlaff, J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
Google Scholar | Crossref11. Neuen, BL, Ohkuma, T, Neal, B, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation 2018; 138: 1537–1350.
Google Scholar | Crossref | Medline12. Higgins, JP, Altman, DG, Gotzsche, PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
Google Scholar | Crossref13. Wheeler, DC, Stefánsson, BV, Jongs, N, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 2021; 9: 22–31.
Google Scholar | Crossref | Medline14. Cannon, CP, Pratley, R, Dagogo-Jack, S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020; 383: 1425–1435.
Google Scholar | Crossref | Medline15. Jardine, MJ, Zhou, Z, Mahaffey, KW, et al. Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial. J Am Soc Nephrol 2020; 31: 1128–1139.
Google Scholar | Crossref | Medline16. Wiviott, SD, Raz, I, Bonaca, MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347–357.
Google Scholar | Crossref | Medline17. Wanner, C, Lachin, JM, Inzucchi, SE, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 2018; 137: 119–129.
Google Scholar | Crossref | Medline18. Wang, C, Zhou, Y, Kong, Z, et al. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab 2019; 21: 1018–1026.
Google Scholar | Crossref | Medline19. Wei, XB, Wei, W, Ding, LL, et al. Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: a network meta-analysis of large randomized trials. Prim Care Diabetes 2021; 15: 208–211.
Google Scholar | Crossref | Medline20. Zhao, LM, Ding, LL, Zhan, ZL, et al. Do all gliflozins reduce stroke in patients with type 2 diabetes mellitus and impaired renal function? J Stroke Cerebrovasc Dis 2021; 30: 105799.
Google Scholar | Crossref | Medline21. Giugliano, D, Esposito, K. Class effect for SGLT-2 inhibitors: a tale of 9 drugs. Cardiovasc Diabetol 2019; 18: 94.
Google Scholar | Crossref | Medline